Halozyme Therapeutics EV/EBIT HALO

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2018.

Today, Oct 23, 2026: 17.4×
9-year median: 20.6×
Against its 9-year history: 31st; percentile: 0 is its lowest day, 100 its highest
9-year range: 11.0× to 105×
Peer median: 24.0×

Halozyme Therapeutics' EV/EBIT is 17.4× as of Oct 23, 2026.

That is below its 9-year median of 20.6×, lower than on 69% of days in the last 9 years.

Over that time it ranged from 11.0× in Dec 2025 to 105× in Feb 2021.

The median for 10 biotech stocks of a similar size is 24.0×.

EV/EBIT over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	17.4×	11.5×	17.4×
2025	12.1×	11.0×	17.3×
2024	14.6×	13.9×	22.5×
2023	19.0×	18.1×	35.0×
2022	35.8×	15.3×	37.2×
2021	19.0×	15.3×	105×
2020	90.1×	79.6×	90.5×
2019	38.1×	32.1×	38.1×
2018	31.0×	21.6×	36.7×

Against its peers

Companies in Biotechnology nearest Halozyme Therapeutics' size, closest first, today.

Company	EV/EBIT
HALOHalozyme Therapeutics	17.4×
NBIXNeurocrine Biosciences	18.2×
EXELExelixis	15.4×
TECHBIO-TECHNE	44.9×
RGENRepligen	160×
KRYSKrystal Biotech	42.4×
INCYIncyte	10.1×
UTHRUnited Therapeutics	16.1×
ALNYAlnylam Pharmaceuticals	27.9×
ONCBeOne Medicines	42.2×
REGNRegeneron Pharmaceuticals	20.0×
Peer median	24.0×

Where Halozyme Therapeutics ranks

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Halozyme Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.